volume 47 issue 31 pages 10330-10343

Why develop photoactivated chemotherapy?

Sylvestre Bonnet 1
1
 
Leiden Institute of Chemistry, Einsteinweg 55, 2333CC Leiden, The Netherlands
Publication typeJournal Article
Publication date2018-06-23
scimago Q2
wos Q1
SJR0.653
CiteScore6.0
Impact factor3.3
ISSN14779226, 14779234
PubMed ID:  29978870
Inorganic Chemistry
Abstract
Photoactivated chemotherapy is an approach where a biologically active compound is protected against interaction with the cell environment by a light-cleavable protecting group, and unprotected by light irradiation. As such, PACT represents a major scientific opportunity for developing new bioactive inorganic compounds. However, the societal impact of this approach will only take off if the PACT field is used to address real societal challenges, i.e., therapeutic questions that make sense in a clinical context, rather than purely chemical questions. In particular, I advocate here that the field has become mature enough to switch from a compound-based approach, where a particular cancer model is chosen only to demonstrate the utility of a compound, to a disease-based approach, where the question of which disease to cure comes first: which PACT compound should I make to solve that particular clinical problem? The advantages and disadvantages of PACT vs. other phototherapeutic techniques are discussed, and a roadmap towards real clinical applications of PACT is drawn.
Found 
Found 

Top-30

Journals

5
10
15
20
25
30
35
Inorganic Chemistry
31 publications, 11.74%
Journal of the American Chemical Society
16 publications, 6.06%
Dalton Transactions
15 publications, 5.68%
Angewandte Chemie - International Edition
13 publications, 4.92%
Angewandte Chemie
13 publications, 4.92%
Journal of Inorganic Biochemistry
10 publications, 3.79%
Coordination Chemistry Reviews
10 publications, 3.79%
Chemical Science
9 publications, 3.41%
Chemistry - A European Journal
8 publications, 3.03%
Journal of Medicinal Chemistry
7 publications, 2.65%
Journal of Biological Inorganic Chemistry
7 publications, 2.65%
Inorganica Chimica Acta
6 publications, 2.27%
Chemical Society Reviews
5 publications, 1.89%
Photochemistry and Photobiology
4 publications, 1.52%
Inorganic Chemistry Frontiers
4 publications, 1.52%
European Journal of Medicinal Chemistry
3 publications, 1.14%
Polyhedron
3 publications, 1.14%
Advanced healthcare materials
3 publications, 1.14%
European Journal of Inorganic Chemistry
3 publications, 1.14%
Chemical Communications
3 publications, 1.14%
Molecules
2 publications, 0.76%
Pharmaceutics
2 publications, 0.76%
Nature Communications
2 publications, 0.76%
Russian Chemical Bulletin
2 publications, 0.76%
Mendeleev Communications
2 publications, 0.76%
Journal of Photochemistry and Photobiology A: Chemistry
2 publications, 0.76%
ChemBioChem
2 publications, 0.76%
Particle and Particle Systems Characterization
2 publications, 0.76%
Applied Organometallic Chemistry
2 publications, 0.76%
5
10
15
20
25
30
35

Publishers

10
20
30
40
50
60
70
American Chemical Society (ACS)
65 publications, 24.62%
Wiley
60 publications, 22.73%
Elsevier
55 publications, 20.83%
Royal Society of Chemistry (RSC)
46 publications, 17.42%
Springer Nature
19 publications, 7.2%
MDPI
10 publications, 3.79%
Frontiers Media S.A.
2 publications, 0.76%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
2 publications, 0.76%
Bentham Science Publishers Ltd.
1 publication, 0.38%
The Endocrine Society
1 publication, 0.38%
Hindawi Limited
1 publication, 0.38%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.38%
10
20
30
40
50
60
70
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
264
Share
Cite this
GOST |
Cite this
GOST Copy
Bonnet S. Why develop photoactivated chemotherapy? // Dalton Transactions. 2018. Vol. 47. No. 31. pp. 10330-10343.
GOST all authors (up to 50) Copy
Bonnet S. Why develop photoactivated chemotherapy? // Dalton Transactions. 2018. Vol. 47. No. 31. pp. 10330-10343.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1039/C8DT01585F
UR - https://doi.org/10.1039/C8DT01585F
TI - Why develop photoactivated chemotherapy?
T2 - Dalton Transactions
AU - Bonnet, Sylvestre
PY - 2018
DA - 2018/06/23
PB - Royal Society of Chemistry (RSC)
SP - 10330-10343
IS - 31
VL - 47
PMID - 29978870
SN - 1477-9226
SN - 1477-9234
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2018_Bonnet,
author = {Sylvestre Bonnet},
title = {Why develop photoactivated chemotherapy?},
journal = {Dalton Transactions},
year = {2018},
volume = {47},
publisher = {Royal Society of Chemistry (RSC)},
month = {jun},
url = {https://doi.org/10.1039/C8DT01585F},
number = {31},
pages = {10330--10343},
doi = {10.1039/C8DT01585F}
}
MLA
Cite this
MLA Copy
Bonnet, Sylvestre. “Why develop photoactivated chemotherapy?.” Dalton Transactions, vol. 47, no. 31, Jun. 2018, pp. 10330-10343. https://doi.org/10.1039/C8DT01585F.